Replies to post #94041 on Biotech Values

[DewDiligence]

TEVA:

Leader Capital Markets analyst Yoav Burgan said, “This is another milestone in Teva's strategic plan to develop a pipeline of brand drugs. Teva's primary objective is to reduce its dependence on Copaxone over time and to gradually change its business mix toward brand drugs.”

That’s an odd thing for an analyst to write; Teva’s own publicly stated goal is to maintain the same mix of generic (70%) and branded (30%) sales that it has today.